Please assess the completion status of the following clinical trial:

Trial Title: Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with myelodysplastic syndrome, (MDS) according to WHO classification (\< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation~2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor (MUD) HLA-identity defined by the following markers: HLA-A, -B, -DRB1, DQB1.~3. Target graft size (unmanipulated) bone marrow: 2 to 10 x 106 CD34+ cells/kg BW recipient or at least 2 x 108 nucleated cells /kg BW or peripheral blood: 4 to 10 x 106 CD34+ cells/kg BW recipient~4. Age \> 18 and \< 60 years~5. Karnofsky Index \> 80 %~6. Adequate contraception in female patients of child-bearing potential~7. Written informed consent~Exclusion Criteria:~1. 'Secondary' or therapy-related MDS with known history of exposure to cytotoxic alkylating drugs and/or radiation therapy~2. Previous AML-induction therapy with more than two courses (e.g. in case of blast excess)~3. Previous allogeneic transplantation~4. Severe concomitant illnesses / medical conditions (e.g. impaired respiratory and/or cardiac function)~5. Known and manifested malignant involvement of the CNS~6. Active infectious disease~7. HIV- positivity or active hepatitis infection~8. Impaired liver function (Bilirubin \> upper normal limit; Transaminases \> 3.0 x upper normal limit)~9. Impaired renal function (Creatinine-clearance \< 60 ml/min; Serum Creatinine \> 1.5 x upper normal limit).~10. Pleural effusion or ascites \> 1.0 L~11. Pregnancy or lactation~12. Known hypersensitivity to treosulfan and/or fludarabine~13. Participation in another experimental drug trial within 4 weeks before study~14. Non-co-operative behaviour or non-compliance~15. Psychiatric diseases or conditions that might impair the ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treosulfan (Type: EXPERIMENTAL): Patients with myelodysplastic syndrome, (MDS) according to WHO classification (\< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).